RxDoctor Payments Data

Ghinwa Nakkash, MD

Internal Medicine · Troy, MINPI 1649253311

Payments from drug & device makers

$381in general payments, 2019–2025

Across 14 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$133
  • Teva Pharmaceuticals USA, Inc.$121
  • Amarin Pharma, Inc.$50
  • Novartis$26
  • Concordia Pharmaceuticals Inc.$19
  • AbbVie$18
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$381100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$133
Teva Pharmaceuticals USA, Inc.1$121
Amarin Pharma, Inc.3$50
Novartis2$26
Concordia Pharmaceuticals Inc.1$19
AbbVie1$18
Lilly USA, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$381 in reported general payments places this provider in the 60th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$43,769
Medicare patients
95
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$117,543
JanuviaSitagliptin Phosphate107$103,484
FarxigaDapagliflozin Propanediol106$88,719
LinzessLinaclotide104$79,938
JardianceEmpagliflozin76$61,408
TrulicityDulaglutide49$53,576
EliquisApixaban35$52,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$26,678
VascepaIcosapent Ethyl44$16,034
Repatha SureclickEvolocumab18$14,419
Incruse ElliptaUmeclidinium Bromide17$7,255
Diclofenac Sodium251$6,133
Advair HfaFluticasone Propion/Salmeterol15$6,105
DapagliflozinDapagliflozin Propanediol11$5,430
Atorvastatin Calcium683$5,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$133$117,54391 claims
AbbVieLinzess$18$79,938104 claims
Lilly USA, LLCTrulicity$14$53,57649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →